-
Djokovic inspired by Serena as he targets history at Wimbledon
-
Thousands ride through Rome as Vespa celebrates 80 years
-
Stokes falls cheaply as England collapse in New Zealand decider
-
Sinner ready for Wimbledon defence despite lack of time on grass
-
Russell bounces back to beat Antonelli in final practice
-
Records tumble as European heatwave moves east
-
Iran says US violated peace deal as both sides trade fire
-
England, Portugal eye top spots as World Cup group stages wrap up
-
Injured Australian pair Leckie, Italiano out of World Cup
-
US, Iran trade strikes putting new strain on Middle East truce
-
Farmers fear drought as Italy's longest river runs dry
-
Thousands expected as Vespa celebrates 80 years in Rome
-
Budapest Pride to push for equality after reversed ban
-
Pino, Williams injuries mar Spain's World Cup progress
-
World Cup fans get taste of American life -- at the mall
-
'Struggle continues' in Bolivia's Morales heartland
-
World Cup turns New York's Times Square into global fan hub
-
Bielsa accepts blame for World Cup exit, but says Uruguay deserved more
-
Lebanon, Israel and US sign trilateral framework pact
-
Uruguay crash out of World Cup as Spain avoid Argentina clash
-
Cape Verde extend World Cup fairytale to set up Argentina meeting
-
Swiss glaciers facing drastic loss from heatwave: expert
-
Messi to start dead-rubber World Cup group match on bench
-
Trump unveils new US passport -- with picture of himself
-
US and Iran trade strikes putting new strain on Mideast ceasefire
-
Hat-trick hero Dembele displays Ballon d'Or brilliance for France at World Cup
-
Maple Leafs make teen McKenna top pick in NHL Draft
-
Injured England defender James to miss Panama game at World Cup
-
California appeals court orders Weinstein resentencing for sex assault
-
Norway coach defends decision to leave out Haaland, Odegaard against France
-
Scheffler fires 60 to grab 36-hole PGA Travelers lead
-
Movie theaters are allies for streamers like us, Apple exec says
-
Austria's Rangnick shuts down conspiracy talk ahead of Algeria World Cup clash
-
DR Congo must take risks to keep World Cup 'dream alive', says Desabre
-
Should we fear an AI bubble bust?
-
Jangoo, Chase keep West Indies in touch against Sri Lanka
-
US strikes Iran sites after cargo ship attack
-
Dembele hat-trick as France swat Norway, Senegal stay alive
-
Gueye double keeps Senegal's World Cup hopes alive
-
Dembele hits hat-trick as France thrash second-string Norway at World Cup
-
US stocks recover from tech tremors as oil prices fall
-
Globalization isn't dead, just 'transformed,' says IMF chief economist
-
OpenAI restricts limited release of new model to US only
-
Israel and Lebanon hail Washington deal, rejected by Hezbollah
-
Scheffler fires 60 to grab early PGA Travelers lead
-
Usyk -- pugilist who kept Ukrainian spirits high in darkest days
-
Trump blasts 'godless' Democrats in incendiary speech to evangelicals
-
Orange wave: Dutch World Cup dream gathers pace
-
Venezuela earthquakes kill 920, tens of thousands missing
-
Swiss nuclear plant shut down due to heatwave
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems.
The Reveal® G4 HIV-1/2 antibody rapid test (Reveal® G4 HIV) is the world's fastest HIV rapid test. Based on MedMira's patented Rapid Vertical Flow Technology, the Reveal® G4 HIV offers a simple testing solution with immediate results which do not fade away. Therefore, offering the best rapid testing solution which is FDA approved since 2004. The Reveal® G4 HIV is offered in three convenient formats (Point-of-Care finger-stick whole blood, Laboratory format Serum/Plasma and venipuncture whole blood) to accommodate any health care setting without the need for timing devices. With its unique built-in procedural and reagent control line, an operator can be assured that each test has been performed correctly.
A unique feature of MedMira's patented technology is the elimination of the prozone (hook) effect, a known common issue in traditional serological tests, where a high concentration of antibodies can lead to false-negative results. MedMira's technology avoids this by ensuring antibody binding occurs in a controlled, localized environment, while excess antibodies are washed away. The result is a highly accurate test that maintains reliability across a wide range of antibody levels.
As MedMira's SDVOSB Vendor, Lovell is excited to bring this product to federal healthcare providers. MedMira is now available through the Department of Veterans Affairs' Federal Supply Schedule (FSS), GSA Advantage, the Defense Logistics Agency's Electronic Catalog (ECAT), and the Department of Defense's Distribution and Pricing Agreement (DAPA). Listing products on contract vehicles with Lovell streamlines the acquisition process while helping government agencies meet their SDVOSB procurement goals.
"We're proud to partner with MedMira to bring an advanced rapid testing solution to federal healthcare providers. The speed and reliability of their Reveal® G4 platform supports clinicians in making timely decisions and improves the care experience for our veterans," said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.
"MedMira is proud to partner with Lovell Government Services, SDVOSB, to support Federal procurement needs through their eCAT, GSA, and VA FSS contract vehicles," said Nicole Crenshaw, VP of Commercial Operations at MedMira. "This strategic partnership provides us with the critical reach into key government markets, enabling greater access to our innovative diagnostic solutions where they're needed most."
About MedMira
MedMira is the developer and owner of Rapid Vertical Flow (RVF)® Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo® and Miriad® brands in global markets. MedMira's HIV rapid test has been the first approved in Canada and the second HIV rapid test approved in the United States.
For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For Media Inquiries:
Markus Meile
[email protected]
902-450-1588
About Lovell Government Services
Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market. Lovell is a three-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.
Learn more at www.lovellgov.com
For Media Inquiries:
Jeff McKay
[email protected]
850-912-4680
SOURCE: MedMira, Inc.
View the original press release on ACCESS Newswire
E.Hall--AT